Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 6 for:    ART-123

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03517501
Recruitment Status : Not yet recruiting
First Posted : May 7, 2018
Last Update Posted : December 17, 2018
Sponsor:
Information provided by (Responsible Party):
Asahi Kasei Pharma America Corporation

Brief Summary:
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.

Condition or disease Intervention/treatment Phase
Sepsis and Coagulopathy Drug: ART-123 Drug: Placebo Comparator - Placebo Phase 3

Detailed Description:
Study is to evaluate if ART-123 given to patients who have severe sepsis complicated by at least one organ dysfunction and coagulopathy can decrease mortality

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
Estimated Study Start Date : July 2019
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: ART-123 Drug: ART-123
Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Other Name: human recombinant thrombomodulin

Placebo Comparator: Placebo Drug: Placebo Comparator - Placebo
Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days




Primary Outcome Measures :
  1. 28 day [ Time Frame: 28 days ]
    All-cause mortality


Secondary Outcome Measures :
  1. 3 months [ Time Frame: 3 months ]
    Follow up of all-cause mortality

  2. Resolution of organ dysfunction through 28 days as measured by: [ Time Frame: 28 days ]
    Shock free and alive days

  3. Resolution of organ dysfunction through 28 days as measured by: [ Time Frame: 28 days ]
    ventilator free and alive days

  4. Resolution of organ dysfunction through 28 days as measured by: [ Time Frame: 28 days ]
    dialysis free and alive days

  5. 6 and 12 months [ Time Frame: 6 or 12 months ]
    Follow-up of all-cause mortality at



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
  2. Subjects with either compelling evidence of infection OR clinical syndromes highly likely to be bacterial in origin, as follows (Please refer to Appendix B):

    1. Compelling objective evidence of bacterial infection and a known site of infection: Objective evidence would be met with a grossly purulent site of infections, Gram stain evidence, confirming a bacterial pathogen from normally sterile fluids (blood, urine, cerebrospinal fluid (CSF), peritoneal fluid, etc.), having either:

      • White Blood Cell (WBC) count greater > 12,000/mm3 or < 4,000/mm3 or > 10% bands within 36 hours of randomization OR
      • Temperature <36°C or fever >38°C
    2. Clinical syndromes highly likely to be bacterial in origin but not compelling

      • White Blood Cell (WBC) count greater > 12,000/mm3 or < 4,000/mm3 or > 10% bands within 36 hours of randomization AND
      • Temperature <36°C or fever >38°C
  3. Current treatment with intravenous antibiotics for the acute bacterial infection (i.e. not prophylactic antibiotics)
  4. Subjects with sepsis-associated organ dysfunction defined by at least one of the following:

    1. Cardiovascular Dysfunction defined as requiring both adequate fluid resuscitation and vasopressors* to maintain Mean Arterial Pressure (MAP) greater than or equal to (≥) 65 mmHg (implies fluid resuscitation alone does not raise MAP to ≥ 65 mmHg), with onset time being the time of vasopressors are initiated (end of surgery if initiated in surgery), with adequate fluid resuscitation defined as:

      • Intravenous administration of at least 20 mL/kg crystalloid or 10 mL/kg colloid infusion within 6 hours.

      OR

      •Central Venous Pressure (CVP) of greater than (>) 8 mmHg or Pulmonary Artery Wedge Pressure (PAWP) of greater than (>) 12 mmHg.

      • If dopamine is the only vasopressor used, the infusion rate must be greater than (>) 5 μg/kg/min (i.e., must be prescribed to support cardio-pulmonary perfusion). If vasopressin is used, it must be given in conjunction with another vasopressor.
    2. Respiratory Dysfunction is defined as the acute need for mechanical ventilation and PaO2/FiO2 ratio of <250 (or < 200 when lung is the site of infection) with onset time being time of intubation prior to first qualifying PaO2:FiO2 (if intubated for surgery and unable to extubate the qualifying time is the end of surgery), with mechanical ventilation defined as any type of ventilation administered via an endotracheal or nasotracheal tube.
  5. Subjects with coagulopathy characterized by an INR >1.40 without other known etiology (e.g., anticoagulant therapy, chronic liver disease), and having an onset at the time of the first blood draw yielding a qualifying result (point of care device INR results must be confirmed by local laboratory).
  6. Subjects with coagulopathy characterized by platelet count that meets any of the below criteria, and having an onset at the time of the first blood draw yielding a qualifying result.

    1. ≥ 20,000/mm3 and ≤ 30,000/mm3 that upon retesting after platelet transfusion is > 30,000/mm3 (qualifying at the time of the first blood draw yielding a result ≥ 20,000/mm3 and ≤ 30,000/mm3)
    2. > 30,000/mm3 to < 150,000/mm3
    3. > 30% decrease in platelet count within 24 hours
  7. First and last qualifying criteria of sepsis associated organ dysfunction (as defined in Inclusion #4), platelet count and INR occurring in ≤ 24 hours

Exclusion Criteria:

Candidates for the study will be excluded if ANY of the following criteria are present:

  1. Subject or Authorized Representative is unable or unwilling to provide informed consent (as applicable per local and country regulations)
  2. Subject is pregnant (positive serum or urine human Chorionic Gonadotropin (hCG)) or breastfeeding or intends to get pregnant within 28 days of enrolling into the study
  3. Subject is < 18 years of age
  4. Body weight ≥ 175 kg
  5. Subject is unwilling to allow transfusion of blood or blood products
  6. Presence of an advance directive to withhold life-sustaining treatment (except Cardiopulmonary Resuscitation), or likely to have life support withdrawn within 24 hours of consent
  7. Subject has had previous treatment with ART-123
  8. Platelet count < 20,000/ mm3 for any reason, or for platelet count ≥ 20,000/mm3 and ≤ 30,000/mm3 that upon retesting after platelet transfusion does not increase > 30,000/mm3
  9. Elevated INR, leukopenia, or thrombocytopenia that is not due to sepsis, (e.g. patients treated by chemotherapy agent). Please refer to Appendix C as an example of agents known to cause myelosuppression that should be evaluated as the cause of potential leukopenia or thrombocytopenia
  10. Inability to randomize patients in ≤ 12 hours after meeting Inclusion # 7 (onset time requirements for sepsis associated organ dysfunction, INR, and platelet count)
  11. ≤ 8 hours remaining from the end of a major surgery having a high risk of post-operative bleeding and randomization (e.g. extensive intraabdominal or intrathoracic dissection, debridement of a large surface area of tissue, complications arising during surgery, problems with hemostasis during surgery, surgeries of long duration, surgeries with large estimated blood loss).

    • Ensures all randomized surgical subjects with a high risk of post-operative bleeding can be dosed no earlier than 12 hours post-operatively, as described in Section 2.6.3. (minimum 8 hour delay before randomization and 4 hour maximum time to dose after randomization)

  12. Stroke within 3 months prior to consent, trauma or major surgery within 3 months prior to consent that may increase the risk of bleeding
  13. Known bleeding diatheses or anatomical anomaly that predisposes to hemorrhage (e.g. hemophilia, hereditary hemorrhagic telangiectasia, esophageal varices, arteriovenous malformation)
  14. Gastrointestinal bleeding (e.g., melena, hematemesis) or genitourinary bleeding within 6 weeks prior to consent unless a corrective interventional procedure has been performed (i.e., therapeutic endoscopy), or there is evidence of complete resolution
  15. Known thrombophilia or a history of deep-vein thrombosis or pulmonary embolism within 3 months prior to consent
  16. Need for full dose anticoagulation therapy (other than IV unfractionated heparin discontinued > 12 hours prior to randomization), full dose or catheter directed thrombolysis, aspirin at a daily dose > 325 mg, long-acting antiplatelet drugs (e.g. clopidogrel, prasugrel, or ticagrelor), dual antiplatelet therapy, and doses of anticoagulants exceeding thromboprophylaxis doses within 72 hours prior to the first dose of study drug (see Appendix D for more detail)
  17. Acute liver failure not due to sepsis, sepsis associated acute liver failure in any patient with a history of cirrhosis, Class C Chronic liver disease (Child-Pugh score of 10-15); (See Appendix E)
  18. Acute pancreatitis where infection has not been documented by a positive blood or abdominal fluid culture or Gram stain consistent with bacterial infection. Also, in the opinion of the investigator the subject is at increased risk for developing hemorrhagic pancreatitis over the duration of the study
  19. Acute renal failure not due to sepsis or chronic renal failure requiring chronic RRT (Renal Replacement Therapy)
  20. Imminent death or anticipated life expectancy < 90 days for any reason other than the acute sepsis
  21. Participation in another research study involving an investigational agent within 30 days prior to consent, or projected study participation before the Day 29 assessment post randomization
  22. Confirmed or suspected endocarditis, malaria, Pneumocystis jiroveci pneumonia, or viral infections associated with hemorrhage (e.g. dengue fever, lassa, ebola, Bolivian) during the current admission

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03517501


Contacts
Layout table for location contacts
Contact: Pamela Allton 781-419-5045 info@akpamerica.com

Sponsors and Collaborators
Asahi Kasei Pharma America Corporation
Investigators
Layout table for investigator information
Study Director: David Fineberg, MD Asahi Kasei Pharma America

Layout table for additonal information
Responsible Party: Asahi Kasei Pharma America Corporation
ClinicalTrials.gov Identifier: NCT03517501     History of Changes
Other Study ID Numbers: AKPA 3-3002
First Posted: May 7, 2018    Key Record Dates
Last Update Posted: December 17, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Blood Coagulation Disorders
Hemostatic Disorders
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders